– April 1, 2010
April 1, 2010
View Issues
-
An Older Patient with Newly Diagnosed Breast Cancer
The patient is an 82-year-old woman referred for management of newly diagnosed breast cancer. She had been well until approximately 10 years prior to this evaluation, when she sustained a myocardial infarction from which she recovered without complication. Subsequently, she was found to have moderate hypertension and hyperlipidemia, which has been managed medically. -
Strategies for Monitoring Tyrosine Kinase Inhibitor Response in Chronic Phase CML and the Role of Second-Line Inhibitors in Disease Management
The seven-year update of IRIS (a phase-3 International Randomized Study of Interferon and STI571), which randomized chronic-phase CML (CP-CML) patients to IFNa/AraC or imatinib (400 mg/d), showed an 81% EFS and 86% OS for imantinib. -
Minimal Activity of the JAK2 Inhibitor CEP 701 in Myelofibrosis
The activation mutation JAK2 tyrosine kinase (JAK2V617F) is found in 50% of patients with myleofibrosis (MF). In this phase-2 study, CEP 701, a JAK2 inhibitor, was administered to MF patients harboring a JAK2 mutation. -
Screening Colonoscopy and the Right Side of the Colon
In an analysis of community-performed colonoscopies in southwestern Germany, the prevalence of left-sided advanced colorectal neoplasms, but not right-sided neoplasms, was strongly reduced within a ten-year period after colonoscopy. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
FDA is reviewing safety of TZDs; SSRI use with tamoxifen; Metformin smells like fish; FDA Actions.